Highly Selective Non-Covalent BTK Inhibitor Pirtobrutinib for B-Cell Malignancies With Richter Transformation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
Lancet Haematol 2024 Jul 18;[EPub Ahead of Print], WG Wierda, NN Shah, CY Cheah, D Lewis, MS Hoffmann, CC Coombs, N Lamanna, S Ma, D Jagadeesh, T Munir, Y Wang, TA Eyre, JM Rhodes, M McKinney, E Lech-Maranda, CS Tam, W Jurczak, K Izutsu, AJ Alencar, MR Patel, JF Seymour, JA Woyach, PA Thompson, PB Abada, C Ho, SC McNeely, N Marella, B Nguyen, C Wang, AS Ruppert, B Nair, H Liu, DE Tsai, LE Roeker, P GhiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.